	US 12,403,123 B2
	Method for treating sickle cell disease using quercetin-containing compositions
Jeffrey I. Zwicker, Boston, MA (US); Bruce Furie, Boston, MA (US); and Robert Flaumenhaft, Boston, MA (US)
Assigned to BETH ISRAEL DEACONESS MEDICAL CENTER, INC., Boston, MA (US)
Filed by Beth Israel Deaconess Medical Center, Inc., Boston, MA (US)
Filed on Jul. 15, 2022, as Appl. No. 17/865,609.
Claims priority of provisional application 63/222,640, filed on Jul. 16, 2021.
Prior Publication US 2023/0029216 A1, Jan. 26, 2023
Int. Cl. A61K 31/352 (2006.01); A61K 31/375 (2006.01); A61K 31/455 (2006.01); A61K 31/519 (2006.01); A61P 7/06 (2006.01)

CPC A61K 31/352 (2013.01) [A61K 31/375 (2013.01); A61K 31/455 (2013.01); A61K 31/519 (2013.01); A61P 7/06 (2018.01)]

11 Claims

1. A method of treating one or more symptoms of sickle cell disease in a subject in need thereof, the method comprising administering to the subject a composition comprising an effective amount of isoquercetin, vitamin B3, and vitamin C,

thereby treating the one or more symptoms of sickle cell disease,

wherein the subject is not currently receiving anticoagulant therapy; and

wherein the one or more symptoms of sickle cell disease are selected from the group consisting of anemia, fatigue, jaundice, painful swelling of the hands and feet, acute chest syndrome, acute pain crisis, sickle cell pain crisis, uncomplicated pain crisis, chronic pain, delayed growth or delayed puberty, eye problems, detached retina, hospitalizations, emergency room visits, and blood transfusions, or any combination thereof.